Kratom Poison Center Reports Climb from 19 to 1,242 in 13 Years as Severe Outcomes Surge
核心洞察
Kratom (搜索)-related reports to U.S. poison centers rose from 19 in 2010 to 1,242 in 2023, with severe outcomes climbing from zero to 158 over the same period.
An analysis of 8,919 exposures found roughly 13% met the severe-outcome threshold, and 34% of all exposures resulted in hospital admission.
States without any kratom (搜索) regulation recorded significantly higher rates of exposure, severe outcomes, hospitalization, and overall healthcare use compared with states that ban kratom.
Reports to American poison centers involving kratom (搜索) climbed from 19 in 2010 to 1,242 in 2023, and the number of those reports involving life-threatening effects, lasting disability, or death rose from zero to 158, according to an analysis of national poison data published in the journal Addiction by a team at the Medical College of Wisconsin.
The numbers matter because kratom (搜索) is not a fringe product. It is sold openly at gas stations, smoke shops, and convenience stores across most of the country as a powder, capsule, shot, gummy, or flavored drink, often marketed for energy, pain, or help getting off opioids. Many people who buy it do not think of it as a drug at all, and the poison center record suggests a meaningful share of them end up needing medical care.
The Numbers Behind the Poison Center Reports
Across the full period the researchers examined, America's Poison Centers logged 8,919 kratom (搜索)-related exposures. About 13 percent met the study's definition of a severe outcome. A total of 5,452 reports, or 61 percent, involved kratom as the only substance named, which removes some of the ambiguity that usually clouds poisoning data.
More than 72% of reported individuals required formal medical evaluation in healthcare facilities. Approximately 34% of all exposures resulted in hospital admission, and 44.5% of admitted patients required critical care management, demonstrating substantial acute morbidity. Adults accounted for 91% of cases, with males representing 69% of exposures.
The clinical effects described in the underlying research are consistent with what emergency physicians report: seizures, abnormal heart rhythms, liver injury, and slowed breathing, with risk climbing when kratom (搜索) is combined with alcohol, benzodiazepines, or opioids. Among single-substance cases, nearly one in seven led to a hospital admission and about one in 16 to a critical care admission.
Pharmacological Mechanisms and Severe Neurological Risks
The primary psychoactive alkaloids in kratom (搜索), mitragynine (搜索) and 7-hydroxymitragynine (搜索), produce complex physiological responses. At lower doses, these compounds exert stimulant effects, whereas higher doses stimulate opioid receptors. Documented severe effects include seizures, coma, profound respiratory depression, and cardiac dysrhythmias. While preclinical models suggest a lower baseline risk of hypoventilation compared to traditional opioids, clinical ingestions can still produce naloxone-responsive respiratory depression.
Mitragynine (搜索) additionally interacts with P-glycoprotein and inhibits cytochrome P450 enzymes 2D6 and 3A4, substantially heightening toxicity risks during co-ingestion with other medications or substances. Polysubstance use appeared in 39% of total poison center reports and was associated with a higher frequency of major life-threatening effects.
A Regulatory Patchwork Drives Geographic Disparities
Senior author Ryan Feldman noted that kratom (搜索) is not scheduled "under the US Controlled Substances Act," which has left individual states to write their own rules. That regulatory patchwork produced the study's most striking finding. Compared with states that ban kratom, states without any kratom regulation recorded significantly higher rates of exposure, severe outcomes, hospitalization, and overall health care use. No significant differences were found among the other regulatory categories.
Poison control center data cannot count everyone who uses kratom (搜索), and the study cannot prove that bans caused the difference. States that ban a product may differ in other ways that affect reporting, and the authors describe their work as observational.
What the middle category does is worth understanding, because most Americans live in it. Consumer protection statutes, often written with industry input, typically require labeling, set a minimum purchase age, and cap the concentration of certain alkaloids. They do not require premarket safety testing, independent potency verification, or adverse event reporting the way drug regulation does. A product sold legally under one of these laws can still vary substantially in strength from batch to batch, which is precisely the condition that makes accidental overdose plausible for someone following the label.
Federal Data Point to a Sharper Recent Spike
A separate federal analysis published by the CDC this year, drawing on the same National Poison Data System, found that kratom (搜索)-related exposure reports rose roughly 1,200 percent between 2015 and 2025, from 258 to a record 3,434. Federal researchers linked the sharp increase in the final year to the emergence of high-potency, semisynthetic formulations, including 7-hydroxymitragynine (搜索), or 7-OH. They also counted 233 kratom-associated deaths across the 11-year period, 79 percent of which involved other substances as well.
That distinction between leaf and concentrate is the single most useful thing for a reader to understand. 7-OH is a minor alkaloid present in trace amounts in the kratom (搜索) leaf. It can also be manufactured, and concentrated versions sold as tablets, shots and gummies act on opioid receptors far more powerfully than leaf products do. The Food and Drug Administration (搜索) has moved to restrict those products, and a standing import alert now covers the volume of kratom entering the country.
Federal regulators have gone further. The Drug Enforcement Administration (搜索) filed notices of intent to place concentrated 7-OH above a set threshold, along with three related compounds, into Schedule I on a temporary basis. DEA Administrator Terrance Cole said the action targets "highly concentrated, synthetic 7-OH products." The Federal Register notice sets the threshold at more than 0.050 percent 7-OH by weight, or more than one milligram per article, language written to capture manufactured concentrates rather than plain leaf. The temporary order can be issued any time on or after August 5, and it takes effect the day it is published.
Fatal Toxicity Profiles and Provider Guidance
Fatal outcomes occurred in 174 reported cases, including 27 single-substance ingestions. Adjudicated single-substance deaths predominantly involved young males found unresponsive or in sudden cardiac arrest, often without identifiable prodromal warning signs, culminating in irreversible anoxic brain injury. Pediatric exposures, though less frequent, produced severe clinical manifestations including agitation, marked central nervous system depression, and neonatal withdrawal symptoms such as tremors, tachycardia, and respiratory distress.
Because routine toxicological drug screens do not detect mitragynine (搜索), clinicians evaluating unexplained seizures, acute altered mental status, or sudden cardiovascular collapse should proactively consider kratom (搜索) toxicity, investigate potential supplement use, and prepare for intensive supportive care.
Who Faces the Most Risk in a Regulatory Gap
The people most exposed are not casual experimenters. Federal filings describe users who report self-treating chronic pain, anxiety, or opioid withdrawal, and who often move from leaf products to concentrated tablets over time. Someone in that position has substituted an unregulated product of unpredictable strength for medical treatment.
Older adults on heart or sedative medications, people with liver disease, and anyone combining kratom (搜索) with alcohol or prescription opioids face an elevated risk of the serious effects poison centers have documented. Adolescents are a concern in states with no minimum purchase age.
Access is the other burden. Someone using concentrated 7-OH daily in a state or country that suddenly restricts it faces involuntary withdrawal on a legal timetable rather than a clinical one. That is a conversation worth having with a clinician before a supply disappears, not after. Nobody should stop or start any substance abruptly based on a news report.
Warning signs that warrant urgent evaluation include seizures, chest pain, a racing or irregular heartbeat, severe confusion, yellowing of the skin or eyes, and slow or shallow breathing. Milder effects such as agitation, nausea, sweating, or insomnia are worth raising with a clinician. Anyone who suspects a poisoning can reach a poison center around the clock at 1-800-222-1222, and a suspected overdose is a 911 call.